Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97


68Ga-PSMA-11 PET/MR Can Be False Positive in Normal Prostatic Tissue.

Ferraro DA, Rupp NJ, Donati OF, Messerli M, Eberli D, Burger IA.

Clin Nucl Med. 2019 Apr;44(4):e291-e293. doi: 10.1097/RLU.0000000000002473.


Diagnostic performance of 68Gallium-PSMA-11 PET/CT to detect significant prostate cancer and comparison with 18FEC PET/CT.

Hoffmann MA, Miederer M, Wieler HJ, Ruf C, Jakobs FM, Schreckenberger M.

Oncotarget. 2017 Nov 14;8(67):111073-111083. doi: 10.18632/oncotarget.22441. eCollection 2017 Dec 19.


Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer.

Park SY, Zacharias C, Harrison C, Fan RE, Kunder C, Hatami N, Giesel F, Ghanouni P, Daniel B, Loening AM, Sonn GA, Iagaru A.

Radiology. 2018 Aug;288(2):495-505. doi: 10.1148/radiol.2018172232. Epub 2018 May 22.


¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.

Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, Guner G, Munari E, Partin AW, Pavlovich CP, Han M, Carter HB, Bivalacqua TJ, Blackford A, Holt D, Dannals RF, Netto GJ, Lodge MA, Mease RC, Pomper MG, Cho SY.

J Nucl Med. 2015 Jul;56(7):1003-1010. doi: 10.2967/jnumed.115.154336. Epub 2015 Jun 11.


Improving Diagnosis of Primary Prostate Cancer With Combined 68Ga-Prostate-Specific Membrane Antigen-HBED-CC Simultaneous PET and Multiparametric MRI and Clinical Parameters.

Jena A, Taneja R, Taneja S, Singh A, Kumar V, Agarwal A, Subramanian N.

AJR Am J Roentgenol. 2018 Dec;211(6):1246-1253. doi: 10.2214/AJR.18.19585. Epub 2018 Oct 9.


Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of 68Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer.

Hofman MS, Eu P, Jackson P, Hong E, Binns D, Iravani A, Murphy D, Mitchell C, Siva S, Hicks RJ, Young JD, Blower PJ, Mullen GE.

J Nucl Med. 2018 Apr;59(4):625-631. doi: 10.2967/jnumed.117.199554. Epub 2017 Oct 6.


Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.

Hofman MS, Hicks RJ, Maurer T, Eiber M.

Radiographics. 2018 Jan-Feb;38(1):200-217. doi: 10.1148/rg.2018170108. Review.


68Ga-PSMA Uptake by Dermatofibroma in a Patient With Prostate Cancer.

Aydin F, Akçal A, Ünal B, Sezgin Göksu S, Güngör F.

Clin Nucl Med. 2017 May;42(5):358-360. doi: 10.1097/RLU.0000000000001591.


68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.

Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, Scarpa L, di Santo G, Roig LG, Maffey-Steffan J, Horninger W, Virgolini IJ.

Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):941-949. doi: 10.1007/s00259-017-3631-6. Epub 2017 Jan 31.


Quantitative characterisation of clinically significant intra-prostatic cancer by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11.

Domachevsky L, Goldberg N, Bernstine H, Nidam M, Groshar D.

Eur Radiol. 2018 Dec;28(12):5275-5283. doi: 10.1007/s00330-018-5484-1. Epub 2018 May 30.


68Ga-PSMA-HBED-CC PET for Differential Diagnosis of Suggestive Lung Lesions in Patients with Prostate Cancer.

Pyka T, Weirich G, Einspieler I, Maurer T, Theisen J, Hatzichristodoulou G, Schwamborn K, Schwaiger M, Eiber M.

J Nucl Med. 2016 Mar;57(3):367-71. doi: 10.2967/jnumed.115.164442. Epub 2015 Nov 19.


68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer.

Fendler WP, Schmidt DF, Wenter V, Thierfelder KM, Zach C, Stief C, Bartenstein P, Kirchner T, Gildehaus FJ, Gratzke C, Faber C.

J Nucl Med. 2016 Nov;57(11):1720-1725. Epub 2016 Jun 3.


Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.

Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L.

J Nucl Med. 2015 Aug;56(8):1185-90. doi: 10.2967/jnumed.115.160382. Epub 2015 Jun 25.


Targeted Prostate Biopsy Using 68Gallium PSMA-PET/CT for Image Guidance.

Simopoulos DN, Natarajan S, Jones TA, Fendler WP, Sisk AE Jr, Marks LS.

Urol Case Rep. 2017 Jun 3;14:11-14. doi: 10.1016/j.eucr.2017.05.006. eCollection 2017 Sep.


68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer.

Vinsensia M, Chyoke PL, Hadaschik B, Holland-Letz T, Moltz J, Kopka K, Rauscher I, Mier W, Schwaiger M, Haberkorn U, Mauer T, Kratochwil C, Eiber M, Giesel FL.

J Nucl Med. 2017 Dec;58(12):1949-1955. doi: 10.2967/jnumed.116.185033. Epub 2017 Jun 21.


Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.

Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G, Doherty A, Gschwend JE, Schwaiger M, Eiber M.

J Nucl Med. 2016 Nov;57(11):1713-1719. Epub 2016 Jun 3.


Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.

Sanli Y, Kuyumcu S, Sanli O, Buyukkaya F, İribaş A, Alcin G, Darendeliler E, Ozluk Y, Yildiz SO, Turkmen C.

Ann Nucl Med. 2017 Nov;31(9):709-717. doi: 10.1007/s12149-017-1207-y. Epub 2017 Sep 12.


Prostate-specific membrane antigen PET/MRI validation of MR textural analysis for detection of transition zone prostate cancer.

Bates A, Miles K.

Eur Radiol. 2017 Dec;27(12):5290-5298. doi: 10.1007/s00330-017-4877-x. Epub 2017 Jun 12.


Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer.

Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, Beer AJ, Wester HJ, Gschwend J, Schwaiger M, Maurer T.

Eur Urol. 2016 Nov;70(5):829-836. doi: 10.1016/j.eururo.2015.12.053. Epub 2016 Jan 18.


PET/CT With 68Ga-PSMA in Prostate Cancer: Radiopharmaceutical Background and Clinical Implications.

Giovacchini G, Giovannini E, Riondato M, Ciarmiello A.

Curr Radiopharm. 2018;11(1):4-13. doi: 10.2174/1874471010666171101121803. Review.


Supplemental Content

Support Center